Should I buy Zimmer Biomet (ZBH) stock or is it too late?

Zimmer Biomet · Health Care · price $99

See the full Zimmer Biomet (ZBH) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (239 calls tested). It aims for $95 (-4.5 %), call made on July 10, 2026, maturing on July 10, 2027 (49 d ago).

The 5 reliable analysts $100+0.5 %

The 8 other firms $98-1.5 %

How to read it: the 5 reliable firms are not filtered by optimism — 3 aim above the price, 2 below, hence their $100 median. “The 8 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Zimmer Biomet

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Citigroup	71 %	+10.3 %	14	$93 -7%
UBS	57 %	+9.7 %	7	$86 -14%
Stifel	33 %	+6.8 %	15	$110 +11%
BTIG	40 %	+4.2 %	5	$112 +13%
Barclays	57 %	+0.3 %	14	$94 -6%
Raymond James	33 %	+0.2 %	21	$113 +14%
Wells Fargo	38 %	-1.2 %	8	$90 -10%
JMP Securities	36 %	-4.6 %	14	$125 +26%

In short — Should you invest in Zimmer Biomet? Is it too late, still worth it? Analysts are split (29% buy, median target $100, i.e. +1%), and the most reliable on ZBH targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

The most reliable firm on ZBH, Truist Securities (100% hit rate, 2 scored calls), targets $106 (call made on August 7, 2026, maturing on August 7, 2027) (+7%) in its most recent call, and $92 (call made on April 29, 2026, maturing on April 29, 2027) (-8%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 14 ratings, 9 are neutral and 1 is a sell.
Limited upside: the median target is only +1% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on ZBH

Median target $100 (+1%) · 14 ratings · Hold consensus

Strong Buy00%

Buy429%

Hold964%

Sell17%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Zimmer Biomet now?

We won't decide for you. The facts: 29% of analysts rate it a buy, median target $100 (+1%), and Truist Securities (most reliable on ZBH, 100%) targets $106. Weigh that against valuation (P/E ~25). This is not personalized advice.

Is it too late to invest in Zimmer Biomet?

The stated upside is small: the median target ($100) sits just +1% from the price ($99) (most reliable on ZBH: Truist Securities, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Zimmer Biomet still worth investing in?

It depends on the gap between the price ($99) and its estimated value: analysts target $100 on median (+1%), with 29% buys (most reliable on ZBH: Truist Securities, 100%). Cross-check with their real reliability on ZBH and the cautions above. Information, not advice.

What's the main risk in buying ZBH?

The consensus is not unanimous: of 14 ratings, 9 are neutral and 1 is a sell.

→ Go deeper: the full Zimmer Biomet profile (consensus, analyst reliability, price target, performance).